Abstract 1928P
Background
Sclerosing Epithelioid Fibrosarcoma (SEF) and Low Grade Fibromyxoid Sarcoma (LGFMS) are ultrarare sarcomas (incidence 0.15 and 0.51/106/year respectively, PMID: 33630918) with close/similar translocations whose natural history and optimal treatment are not well known. We report on the nationwide exhaustive series of 330 patients with SEF or LGFMS in NETSARC+ since 2010.
Methods
NETSARC (netsarc.org) is a network of 26 reference sarcoma centers with specialized multidisciplinary tumor boards (MDTB). Since 2010, pathological review is mandatory for sarcoma patients and patients’ characteristics are collected in the NETSARC+ nationwide database. The characteristics of patients with SEF and LGFMS and their outcome are presented and compared.
Results
35/73 (47.9%) and 125/257(48,8%) of patients with SEF and LGFMS were female. More primary visceral, bone and trunk primary sites were observed in SEF (p<0.001). 30.1% of SEF vs 4.3% of LGFMS were metastatic at diagnosis (p<0.0001). Median size of the primary tumor was 51mm (range 10-90). For LGFMS vs 80mm (20-320) for SEF (p<0.001). Median age of LGFMS was 12 years younger than that of SEF (43 [range 4-98] vs 55 [range 10-91], p<0.001). Neoadjuvant treatment was more often given to SEF (16.4% vs 8.6%, p=0.05). More patients with LGFMS were operated first in reference centers (51% vs 26%, p<0.001).The R0 rate was 41% in LGFMS vs 16% in SEF (p<0.001). Median PFS of SEF and LGFMS were 32 and 136 months (p<0.0001) respectively. The median OS was not reached. 50-months OS was 92.6% vs 81% fr SEF (p=0.05). Median survival was 77 months after first relapse, similar for SEF and LGFMS. In multivariate analysis for PFS, SEF histotype, size of the tumor, met at diagnosis were independently correlated to survival. In multivariate analysis for OS, age, size of the tumor, met at diagnosis, but not SEF, independently correlated to survival.
Conclusions
Although sharing close molecular alterations, SEF and LGFMS have a very different natural history, clinical presentation and outcome with a higher risk of metastatic relapse in SEF. Survival after relapse is longer than with other sarcomas, and similar for SEF and LGFMS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Centre Leon Bérard for NETSARC+ Network.
Funding
NetSARC+ (INCA & DGOS) and RREPS (INCA & DGOS), RESOS (INCA & DGOS), LYRICAN+ (INCA-DGOS-INSERM 12563), Eurosarc (FP7-278742), InterSARC (INCA), LabEx DEvweCAN (ANR-10-LABX-0061), EURACAN (EC 739521), Association DAM’s, la Fondation ARC, Infosarcome, Ligue de L’Ain contre le Cancer, La Ligue contre le Cancer funded this study.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1982P - Transcriptomic analysis and tumor microenvironment (TME) classification reveals unique immune biology in HIV patients with Kaposi sarcoma (KS)
Presenter: Jihua Yang
Session: Poster session 15
1983P - Palliative spatially fractionated stereotactic radiation therapy (Lattice) for large sarcoma
Presenter: Gabriela Studer
Session: Poster session 15
1984P - Sex differences in anticancer treatment delivery and toxicity in patients with sarcoma in a reference center
Presenter: Ilaria Tortorelli
Session: Poster session 15
1985P - Expert sarcoma care is the need of the hour: Diagnostic and management challenges at a tertiary-care centre in India
Presenter: Ghazal Tansir
Session: Poster session 15
1986P - Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: An analysis from the OnCovid registry
Presenter: Alessandro Mazzocca
Session: Poster session 15
1987TiP - Pembrolizumab in combination with eftilagimod alpha and radiotherapy in neoadjuvant treatment of patients with soft tissue sarcomas: EFTISARC-NEO trial
Presenter: Katarzyna Kozak
Session: Poster session 15
2213P - Impact of the diagnosis-to-treatment interval on the survival of patients with papillary thyroid cancer
Presenter: Tingting Wei
Session: Poster session 15
2214P - Identification of prognosis-associated genes in locally advanced well-differentiated thyroid cancer using TCGA cohort analysis
Presenter: Ah Ra Jung
Session: Poster session 15
2216P - Clinicopathologic and genetic characteristics of patients of different ages with diffuse sclerosing variant papillary thyroid carcinoma
Presenter: Soo Young Kim
Session: Poster session 15
2220P - MOLTHY project (TTCC-2020-02): A Spanish observational study for MOLecular characterization of THYroid carcinoma
Presenter: Neus Baste Rotllan
Session: Poster session 15